Breaking News

Aptuit Appoints BD EVP

July 16, 2014

Upgrades cytotoxic capabilities at Glasgow

Paul D. Overton, Ph.D., has been appointed executive vice president of business development and marketing at Aptuit, responsible for all of the company’s sales and marketing activities. Dr. Overton will be based in the UK, reporting to Jonathan Goldman, M.D., Aptuit's chief executive officer, and will serve as a member of the executive committee. 
Dr. Overton has successfully led the global sales, marketing and program management team at Huntingdon Life Sciences, growing the business despite challenges in the non-clinical CRO market, and was instrumental in developing late stage discovery and translational sciences partnerships. Prior to Huntingdon, he held leadership positions at Covance Laboratories, LCG Biosciences, Origin Pharmaceutical Services, and Cambridge Life Sciences.
Dr. Goldman said, "Paul's expertise in business development, marketing and corporate leadership, as well as his hands-on work as a scientist, give him a unique skill set that will greatly benefit our clients and help in advancing Aptuit's position as a market leader. Our team of global sales professionals has a strong understanding of market needs, and their approach to customer partnerships and problem solving will be enhanced under Paul's leadership."
Additionally, the company recently invested $1 million at its Glasgow site in Scotland, upgrading sterile cytotoxic liquid and lyophilized drug product manufacturing capabilities for GMP clinical supply, which will be operational by January 2015. The company installed an autofiller with Restricted Access Barrier Technology (RABs) to enable larger batch sizes for liquid and lyophilized drug products, increasing capacities from 2,000 units to more than 9,000 units.

Related Contract Manufacturing:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks